Long-term survival results favor chemotherapy before surgery for locally advanced breast cancer

April 26, 2002

CHAPEL HILL - Long-term survival results from a breast cancer treatment study begun in 1992 at the University of North Carolina at Chapel Hill's Lineberger Comprehensive Cancer Center strongly favor chemotherapy followed by surgery for women with large, locally advanced tumors.

Traditionally, women with breast cancer receive surgery followed by chemotherapy. However, the new findings also show that chemotherapy followed by surgery - neoadjuvant therapy - often allows less drastic and breast-sparing surgery, lumpectomy versus mastectomy.

Despite efforts at early detection, locally advanced breast cancer remains prevalent and is a challenge to control. In the past, many of these patients were considered inoperable because of the sheer volume of their tumors and the belief that they would soon die from spread of the disease well beyond the breast, or distant metastatic disease.

Over the last decade, studies of neoadjuvant therapy for patients with large primary tumors had demonstrated that successful tumor downstaging, or improvement, could result in increased rates of breast-conserving therapy. Moreover, a few reports indicated that tumors larger than three centimeters that were successfully downstaged with neoadjuvant chemotherapy could be controlled.

Still, the overall effect on long-term survival has remained unclear; the new findings help clarify this issue.

At a median follow up of 70 months, 76 percent of patients in the UNC study who received neoadjuvant therapy survived for at least of five years. Post-treatment follow up ranged from 35 to 117 months.

In addition, neoadjuvant therapy may make surgery a viable option for women whose tumors were considered inoperable due to their seriously advanced stage, said Dr. William G. Cance, professor of surgery, chief of surgical oncology and a member of the cancer center.

"I think this study now provides a surgical advantage for women with locally advanced breast cancer who undergo neoadjuvant therapy," he said.

Cance presented the follow-up results April 25 at the 122nd Annual Meeting of the American Surgical Association in Hot Springs, Va. Cance, along with UNC colleagues Drs. Mark Graham II and Julian Rosenman, wrote the original protocol for the study, which ended in 1998. Drs. Lisa A. Carey, Benjamin F. Calvo and David W. Ollila also joined the study.

"This is among the longest follow ups in neoadjuvant therapy nationally," Cance said, adding that the treatment regimen used was aggressive, dose-intense and time-intense.

It was also one of the briefest treatments used, he added. "Our neoadjuvant treatment protocol emphasized timely completion of all modalities of therapy - chemotherapy, surgery, post-operative chemotherapy and radiation therapy - within 32 weeks, with minimal interval between modalities," he said.

The 62 women studied all had locally advanced primary breast tumors greater than five centimeters, with skin or chest wall involvement, or with extensive involvement of the axillary (armpit) lymph nodes. The median age was 44 years, and roughly two-thirds were white and one-third were black. At diagnosis, 51 (82 percent) of the patients had tumors at clinical stage III, with 34 at stage IIIA and 17 at stage IIIB. Three patients were considered at stage IV. In addition, 13 patients (21 percent) had inflammatory breast cancer, which traditionally has been thought to have a poor prognosis.

Overall, 84 percent of patients showed a significant clinical response to chemotherapy. No patient's tumor worsened while taking dose-intense neoadjuvant treatment with doxorubicin. A total of 28 patients (45 percent) had sufficient downstaging of their tumor to permit an attempt at breast conserving therapy, or lumpectomy (segmental mastectomy). Of these, 22 (79 percent) had successful breast preservation, while six required complete mastectomy due to laboratory determination of cancer in the margins of surgery after lumpectomy.

Patients with inflammatory breast disease were not considered candidates for breast-conserving therapy, regardless of clinical response to chemotherapy. When this group was discounted statistically, of the 49 remaining patients, 22 (45 percent) had successful breast conservation, Cance said.

"Our results demonstrate that patients with locally advanced breast cancer can achieve outstanding control of disease and long-term survival by undergoing a dose- and time-intensive regimen of neoadjuvant chemotherapy," he said.

"These data provide evidence that breast conservation can reasonably be accomplished in up to 45 percent of patients with non-inflammatory locally advanced breast cancer," Cance said. "Furthermore, the tumor response to chemotherapy can help identify the subgroup of patients with a more favorable long-term prognosis. Those patients who have clinical downstaging of their tumors and are candidates for breast conserving therapy have the best long-term outcome."

He added that patients who had mastectomy - while at higher risk of relapse as well as development of new tumors in the other breast - still have five-year survival rates of more than 50 percent.

"Thus, dose-intense and time-intense neoadjuvant therapy should be standard care for patients with locally advanced breast cancer," he said.
-end-
By LESLIE H. LANG

Note: Contact Cance at (919) 966-5221or cance@med.unc.edu
School of Medicine contact: Les Lang at (919) 843-9687 or llang@med.unc.edu

University of North Carolina Health Care

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.